Evidence in Practice
Detailed results from the FOURIER cardiovascular outcomes trial on evolocumab were presented at a late-breaking oral presentation at the American College of Cardiology meeting in Washington DC recently. This is the first major outcomes study to be published for a PCSK9 inhibitor – a new class of cholesterol-lowering medicines.
A new study questions the feasibility and value of primary care screening for peripheral arterial disease (PAD). The PIPETTE study is the first UK study of PAD prevalence for nearly a decade.
Low socioeconomic status is linked to significant reductions in life expectancy and should be considered a major risk factor for ill health and early death in national and global health policies, according to a new study of 1.7 million people.
A new study shows that increased activity in the amygdala (the part of the brain involved in stress) is associated with a greater risk of heart disease and stroke. This study provides new insights into the possible mechanism by which stress can lead to cardiovascular disease in humans.
Offering smokers a taster session at an NHS Stop Smoking Service and explaining their personal risk of developing smoking-related diseases doubles their likelihood of attending a stop smoking course.
Liraglutide 1.2 mg has proved cost-effective when compared to alternative daily administered GLP-1 receptor agonists for the treatment of type 2 diabetes in the UK.
A French observational study has found that use of a beta-blocker early after myocardial infarction (MI) (within 48 hours) is associated with a substantial reduction in 30-day mortality in people who do not have heart failure. However, continuing with beta-blockers was not associated with a significant reduction in mortality at 1 year.